Buys | $1,549,944 | 1 | 4 |
Sells | $5,235,540 | 22 | 96 |
RA CAPITAL MANAGEMENT, L.P. | 1 | $1.55M | 0 | $0 | $1.55M | |
GRAYZEL DAVID S. | director | 0 | $0 | 1 | $334,478 | $-334,478 |
Verwijs Marinus | CHIEF TECHNICAL OFFICER | 0 | $0 | 4 | $599,571 | $-599,571 |
Gillies Hunter | CHIEF MEDICAL OFFICER | 0 | $0 | 5 | $767,410 | $-767,410 |
Eldridge George A | SEE REMARKS | 0 | $0 | 3 | $967,049 | $-967,049 |
NOYES TIMOTHY P | CHIEF EXECUTIVE OFFICER | 0 | $0 | 4 | $993,705 | $-993,705 |
Dake Benjamin T | SEE REMARKS | 0 | $0 | 5 | $1.57M | $-1.57M |
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Over the last 12 months, insiders at Aerovate Therapeutics, Inc. have bought $1.55M and sold $5.24M worth of Aerovate Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aerovate Therapeutics, Inc. have bought $71.77M and sold $8.79M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $1.55M.
The last purchase of 928,110 shares for transaction amount of $1.55M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑06‑17.
2024-06-17 | RA CAPITAL MANAGEMENT, L.P. | 928,110 0.2418% | $1.67 | $1.55M | +43.03% | |||
2024-06-14 | Sale | Eldridge George A | SEE REMARKS | 15,000 0.0586% | $25.03 | $375,450 | -90.45% | |
2024-06-14 | Sale | Verwijs Marinus | CHIEF TECHNICAL OFFICER | 10,600 0.0413% | $25.00 | $265,000 | -90.45% | |
2024-06-13 | Sale | Gillies Hunter | CHIEF MEDICAL OFFICER | 6,000 0.0229% | $24.50 | $147,000 | -90.40% | |
2024-05-17 | Sale | Gillies Hunter | CHIEF MEDICAL OFFICER | 4,000 0.0136% | $21.08 | $84,332 | -88.19% | |
2024-05-16 | Sale | NOYES TIMOTHY P | CHIEF EXECUTIVE OFFICER | 10,000 0.0347% | $21.58 | $215,755 | -88.91% | |
2024-05-02 | Sale | Verwijs Marinus | CHIEF TECHNICAL OFFICER | 1,981 0.007% | $21.02 | $41,631 | -88.19% | |
2024-05-01 | Sale | NOYES TIMOTHY P | CHIEF EXECUTIVE OFFICER | 11,357 0.0386% | $20.34 | $230,946 | -88.24% | |
2024-04-17 | Sale | Gillies Hunter | CHIEF MEDICAL OFFICER | 4,000 0.0143% | $22.38 | $89,522 | -89.02% | |
2024-04-17 | Sale | Dake Benjamin T | SEE REMARKS | 6,853 0.0245% | $22.37 | $153,327 | -89.02% | |
2024-04-16 | Sale | NOYES TIMOTHY P | CHIEF EXECUTIVE OFFICER | 10,000 0.0375% | $24.70 | $246,971 | -89.54% | |
2024-04-10 | Sale | Eldridge George A | SEE REMARKS | 7,500 0.0268% | $26.85 | $201,392 | -90.86% | |
2024-04-09 | Sale | GRAYZEL DAVID S. | director | 11,882 0.0428% | $28.15 | $334,478 | -91.19% | |
2024-04-01 | Sale | Eldridge George A | SEE REMARKS | 12,495 0.0455% | $31.23 | $390,208 | -91.95% | |
2024-04-01 | Sale | Dake Benjamin T | SEE REMARKS | 3,325 0.0124% | $31.97 | $106,317 | -91.95% | |
2024-04-01 | Sale | Verwijs Marinus | CHIEF TECHNICAL OFFICER | 5,300 0.0181% | $29.19 | $154,697 | -91.95% | |
2024-04-01 | Sale | NOYES TIMOTHY P | CHIEF EXECUTIVE OFFICER | 10,000 0.035% | $30.00 | $300,033 | -91.95% | |
2024-03-28 | Sale | Gillies Hunter | CHIEF MEDICAL OFFICER | 9,000 0.0322% | $29.50 | $265,500 | -91.62% | |
2024-03-27 | Sale | Dake Benjamin T | SEE REMARKS | 11,068 0.0393% | $27.97 | $309,519 | -91.30% | |
2024-03-25 | Sale | Dake Benjamin T | SEE REMARKS | 3,432 0.0129% | $28.01 | $96,119 | -90.72% |
RA CAPITAL MANAGEMENT, L.P. | 7893678 27.3379% | $19.5M | 2 | 0 | <0.0001% | |
GRAYZEL DAVID S. | director | 14502 0.0502% | $35,819.94 | 1 | 1 | <0.0001% |
Sofinnova Venture Partners X, L.P. | 10 percent owner | 3758686 13.0173% | $9.28M | 1 | 0 | <0.0001% |
Katabi Maha | 3758686 13.0173% | $9.28M | 1 | 0 | <0.0001% | |
Atlas Venture Fund XII, L.P. | 10 percent owner | 3103879 10.7496% | $7.67M | 1 | 0 | <0.0001% |
$2,600,095 | 110 | 13.50% | $70.91M | |
$2,942,496 | 100 | 17.32% | $66.91M | |
$4,898,715 | 46 | 40.74% | $73.28M | |
$329,102,560 | 42 | 30.96% | $73.82M | |
$542,300 | 40 | -14.44% | $67.8M |
Increased Positions | 50 | +60.24% | 8M | +29.15% |
Decreased Positions | 33 | -39.76% | 6M | -20.04% |
New Positions | 25 | New | 6M | New |
Sold Out Positions | 21 | Sold Out | 5M | Sold Out |
Total Postitions | 100 | +20.48% | 30M | +9.11% |
Ra Capital Management, L.P. | $22,337.00 | 31.7% | 9.19M | 0 | 0% | 2024-12-31 |
Sofinnova Investments, Inc. | $9,134.00 | 12.96% | 3.76M | 0 | 0% | 2024-12-31 |
Tcg Crossover Management, Llc | $5,445.00 | 7.73% | 2.24M | 0 | 0% | 2024-12-31 |
Atlas Venture Life Science Advisors, Llc | $4,372.00 | 6.2% | 1.8M | 0 | 0% | 2024-12-31 |
Braidwell Lp | $3,500.00 | 4.97% | 1.44M | +1M | New | 2024-12-31 |
Logos Global Management Lp | $3,402.00 | 4.83% | 1.4M | +1M | New | 2024-12-31 |
Vanguard Group Inc | $2,435.00 | 3.46% | 1M | -149,974 | -13.02% | 2024-12-31 |
Blackrock, Inc. | $2,370.00 | 3.36% | 975,423 | +21,747 | +2.28% | 2024-12-31 |
Adar1 Capital Management, Llc | $2,255.00 | 3.2% | 928,016 | +814,941 | +720.71% | 2024-12-31 |
Allostery Investments Lp | $2,067.00 | 2.93% | 850,684 | +850,684 | New | 2024-12-31 |